Clinical trial · Interventional
Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC
NCT03614065CI-TRIAL-00034128unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observe the effect os radiotherapy plus or not plus endostar in the treatment of brain metastasis in NSCLC
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| endostar | Drug | — | UNRESOLVED |
| Placebos | Drug | — | UNRESOLVED |
| radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- arm a
- description
- This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
- interventionNames
- Drug: Placebos
- Radiation: radiotherapy
- type
- EXPERIMENTAL
- label
- arm b
- description
- This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
- interventionNames
- Drug: endostar
- Radiation: radiotherapy
Primary outcomes (1)
- measure
- Progression Free Survival (PFS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * NSCLC Brain metastasis Exclusion Criteria: * KPS\<60
References
Publications (0)
Data not yet available
No reference posted for this study.